All Type of News
Reason why melanoma therapy Zelboraf failed to be registered for insurance benefit
A Roche Korea’s metastatic melanoma treatment ‘Zelboraf(vemurafenib)’ is a drug which still has not been registered in the drug insurance benefit list for more than 4 years after acquiring commercialization approval i...
Public hearing to legislate ‘Public Pharma Establishment Law’
Assemblyperson Mi-Hyuk Kwon(proportional representative) from The Minjoo Party is planning to hold a public hearing to legislate the ‘Public Pharmaceutical Company Establishment and Management Act’ in response to publ...
Will Avastin be administered in ophthalmology field having no approval?
The government is working on legislating an act to allow hospitals and clinics having no IRB(Institutional Review Board) to widely use pharmaceutical products officially notified by President of the Health Insurance R...
Samsung Bioepis begins to nullify Herceptin’s patent
Samsung Bioepis has started to prepare for a launch of Herceptin(generic name: trastuzumab) biosimilar, a breast cancer treatment, in Korea.
According to the Intellectual Property Tribunal, Samsung Bioepis filed a (...
Amgen overcomes insurance benefit for Blincyto
It is expected Amgen will begin to aggressively target the domestic antibody market.
In the ‘Amendment to the Public Announcement about Drugs Prescribed and Administered on Cancer Patients’ notified by the Health Ins...
Countdown for AIDS treatment overcoming ‘Stribild’ to launch in Korea
A Gilead Sciences’ new 4-substance complex drug ‘Genvoya’ acquired approval to commercialize in Korea. Thus, Gilead is expected to consolidate its position in the HIV treatment market.
According to the industry conc...
Multinational companies’ supply of products with less than 6-month expiration date
Multinational pharmaceutical companies have caused issues as constantly providing products with less than 6-month expiration periods to pharmaceutical distribution companies as an excuse of the out-of-stock crisis on ...
CorePharm succeeds in avoiding Astellas’ patent by salt modification
While a series of domestic companies’ challenges to substance patents all went in vein after implementation of the Patent Linkage System on March 2015, a ruling was made in favor of a Korean challenger at the defensiv...
“Topic is illegality,” multinational pharmas to stand as witness at National Inspection
Two multinational pharmaceutical companies will be summoned for this year’s national inspection. They are Novartis Korea and Janssen Korea; its topic is ‘illegality.’
The Ruling-Opposition Parties’ Room for National ...
“Pharma industry must be cautious on custom to provide KRW 400k accommodation per day”
The ‘Anti-Corruption and Bribery Prohibition Law,’ also known as the ‘Kim Young-Ran Law,’ is about to be enforced in less than 10 days.
While guidelines for governmental departments and the press have been released, ...
